Proactive Investors - Run By Investors For Investors

Akers Biosciences Inc now in "every place where it’s important to be"

Raymond Akers, founder and executive chairman of Akers Biosciences Inc (NASDAQ:AKER, LON:AKR), says “this is gonna be a great year” after a “blazing start” to 2016.
The diagnostic test maker has been granted a US patent for the technology at the heart of a test that detects an allergy to the blood thinning drug Heparin.
The patent was just the tip of the iceberg as the group expands its reach. “We now have distribution in 33 countries around the world," says Akers who added the US$2.5mln order it received from China was a “taste of things to come.”

Meet Gold Road Resources Ltd, Cellmid Ltd, Gold Road Resources Ltd, Altech Chemicals Ltd and Silver City Minerals Ltd at our event, Sydney, 03 October 2017. Register here »
Why Invest In Akers Biosciences, Inc.? Read More Here

Register here to be notified of future Akers Biosciences, Inc. articles
View full AKR profile View Profile

Akers Biosciences, Inc. Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use